Robson, Mark

Publications

Sort by

Co-Author Network

selected publications

Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Academic Article GET IT
Times cited: 146
Illustrating Cancer Risk: Patient Risk Communication Preferences and Interest regarding a Novel BRCA1/2 Genetic Risk Modifier Test. Public health genomics. 2020 Academic Article GET IT
Times cited: 6
Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings. Cancer. 2020 Academic Article GET IT
Times cited: 33
Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Academic Article GET IT
Times cited: 69
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature genetics. 2020 Academic Article GET IT
Times cited: 113
Author Correction: Tumour lineage shapes BRCA-mediated phenotypes. 2020 GET IT
Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Academic Article GET IT
Times cited: 23
Fumarate hydratase FH c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma. Human mutation. 2019 Academic Article GET IT
Times cited: 27
Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2019 Academic Article GET IT
Times cited: 10
Tumour lineage shapes BRCA-mediated phenotypes. Nature. 2019 Academic Article GET IT
Times cited: 291
RE: BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis. Journal of the National Cancer Institute. 2019 Letter GET IT
Times cited: 7
Toward automation of germline variant curation in clinical cancer genetics. Genetics in medicine : official journal of the American College of Medical Genetics. 2019 Academic Article GET IT
Times cited: 27
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American journal of human genetics. 2018 Academic Article GET IT
Times cited: 669
Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2018 Academic Article GET IT
Times cited: 420
Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. Journal of the National Cancer Institute. 2018 Academic Article GET IT
Times cited: 183
Genome doubling shapes the evolution and prognosis of advanced cancers. Nature genetics. 2018 Academic Article GET IT
Times cited: 377
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Annals of oncology : official journal of the European Society for Medical Oncology. 2018 Academic Article GET IT
Times cited: 170
Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. Cancer discovery. 2017 Academic Article GET IT
Times cited: 289
Association of Common Genetic Variants With Contralateral Breast Cancer Risk in the WECARE Study. Journal of the National Cancer Institute. 2017 Academic Article GET IT
Times cited: 26
Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA. 2017 Academic Article GET IT
Times cited: 369
Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell stem cell. 2017 Academic Article GET IT
Times cited: 586
Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. Journal of the National Cancer Institute. 2017 Academic Article GET IT
Times cited: 222
Interest and Attitudes of Patients With Advanced Cancer With Regard to Secondary Germline Findings From Tumor Genomic Profiling. Journal of oncology practice. 2017 Academic Article GET IT
Times cited: 28
SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway. Breast cancer research and treatment. 2017 Academic Article GET IT
Times cited: 16
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature genetics. 2017 Academic Article GET IT
Times cited: 316
Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers. Breast cancer research and treatment. 2017 Academic Article GET IT
Times cited: 80
Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer. Breast cancer research and treatment. 2017 Academic Article GET IT
Times cited: 14
Reply to R.L. Nussbaum et al and J.S. Dolinsky et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Article GET IT
Times cited: 1
Population Frequency of Germline BRCA1/2 Mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Letter GET IT
Times cited: 56
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast cancer research and treatment. 2016 Academic Article GET IT
Times cited: 19
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future oncology (London, England). 2016 Academic Article GET IT
Times cited: 43
Educational and Psychosocial Support Needs in Lynch Syndrome: Implementation and Assessment of an Educational Workshop and Support Group. Journal of genetic counseling. 2016 Academic Article GET IT
Times cited: 11
Body mass index, weight change, and risk of second primary breast cancer in the WECARE study: influence of estrogen receptor status of the first breast cancer. Cancer medicine. 2016 Academic Article GET IT
Times cited: 18
Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 144
A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer. Cancer discovery. 2016 Academic Article GET IT
Times cited: 41
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. The New England journal of medicine. 2016 Academic Article GET IT
Times cited: 1251
Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nature reviews. Clinical oncology. 2016 Review GET IT
Times cited: 257
Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 142
Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. American journal of human genetics. 2016 Academic Article GET IT
Times cited: 100
An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast cancer research and treatment. 2016 Academic Article GET IT
Times cited: 28
Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature communications. 2016 Academic Article GET IT
Times cited: 83
Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Academic Article GET IT
Times cited: 192
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast cancer research : BCR. 2016 Academic Article GET IT
Times cited: 87
Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status. Cancer. 2016 Academic Article GET IT
Times cited: 23
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute. 2015 Academic Article GET IT
Times cited: 85
Identification of germline genetic mutations in patients with pancreatic cancer. Cancer. 2015 Academic Article GET IT
Times cited: 172
American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 327
Gene-panel sequencing and the prediction of breast-cancer risk. The New England journal of medicine. 2015 Academic Article GET IT
Times cited: 729
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic oncology. 2015 Information Resource GET IT
Times cited: 11
An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast cancer research : BCR. 2015 Academic Article GET IT
Times cited: 30
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA. 2015 Academic Article GET IT
Times cited: 400
Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. PloS one. 2015 Academic Article GET IT
Times cited: 33
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast cancer research : BCR. 2014 Academic Article GET IT
Times cited: 45
Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast cancer research : BCR. 2014 Academic Article GET IT
Times cited: 97
Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole. Steroids. 2014 Academic Article GET IT
Times cited: 38
Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?. BMC medicine. 2014 Academic Article GET IT
Times cited: 34
Multigene panel testing: planning the next generation of research studies in clinical cancer genetics. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Editorial Article GET IT
Times cited: 35
Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families. Breast cancer research and treatment. 2014 Academic Article GET IT
Times cited: 6
DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. PLoS genetics. 2014 Academic Article GET IT
Times cited: 45
A prior diagnosis of breast cancer is a risk factor for breast cancer in BRCA1 and BRCA2 carriers. Current oncology (Toronto, Ont.). 2014 Academic Article GET IT
Times cited: 10
A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clinical breast cancer. 2013 Academic Article GET IT
Times cited: 69
Revealing the incidentalome when targeting the tumor genome. JAMA. 2013 Article GET IT
Times cited: 55
Assessment of SLX4 Mutations in Hereditary Breast Cancers. PloS one. 2013 Academic Article GET IT
Times cited: 34
Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report. European journal of cancer. 2013 Academic Article GET IT
Times cited: 67
Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer. Annals of surgical oncology. 2013 Review GET IT
Times cited: 120
Black race as a prognostic factor in triple-negative breast cancer patients treated with breast-conserving therapy: a large, single-institution retrospective analysis. Breast cancer research and treatment. 2013 Academic Article GET IT
Times cited: 16
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature genetics. 2013 Academic Article GET IT
Times cited: 464
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS genetics. 2013 Academic Article GET IT
Times cited: 222
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS genetics. 2013 Academic Article GET IT
Times cited: 97
TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression. Molecular endocrinology (Baltimore, Md.). 2013 Academic Article GET IT
Times cited: 45
Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Science translational medicine. 2013 Academic Article GET IT
Times cited: 395
Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?. Breast cancer research and treatment. 2013 Academic Article GET IT
Times cited: 25
Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies. PLoS genetics. 2013 Academic Article GET IT
Times cited: 43
Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. Cancer. 2012 Academic Article GET IT
Times cited: 34
Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PloS one. 2012 Academic Article GET IT
Times cited: 51
Rare de novo germline copy-number variation in testicular cancer. American journal of human genetics. 2012 Academic Article GET IT
Times cited: 17
A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2012 Academic Article GET IT
Times cited: 19
Screening for germline EGFR T790M mutations through lung cancer genotyping. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2012 Academic Article GET IT
Times cited: 106
Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy. Cancer. 2012 Academic Article GET IT
Times cited: 51
Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2012 Academic Article GET IT
Times cited: 44
What women with breast cancer discuss with clinicians about risk for their adolescent daughters. Journal of psychosocial oncology. 2012 Academic Article GET IT
Times cited: 11
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2011 Academic Article GET IT
Times cited: 532
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast cancer research : BCR. 2011 Academic Article GET IT
Times cited: 63
Do women remain at risk even if they do not inherit a familial BRCA1/2 mutation?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Editorial Article GET IT
Times cited: 5
An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. The oncologist. 2011 Academic Article GET IT
Times cited: 221
Should the presence of germline BRCA1/2 mutations influence treatment selection in breast cancer?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Editorial Article GET IT
Times cited: 8
Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. Human molecular genetics. 2011 Academic Article GET IT
Times cited: 67
Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer. BJU international. 2011 Academic Article GET IT
Times cited: 42
Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer. 2011 Academic Article GET IT
Times cited: 69
Health literacy, numeracy, and interpretation of graphical breast cancer risk estimates. Patient education and counseling. 2011 Academic Article GET IT
Times cited: 66
Germline PALB2 mutation analysis in breast-pancreas cancer families. Journal of medical genetics. 2011 Academic Article GET IT
Times cited: 28
Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women. Breast cancer research and treatment. 2011 Academic Article GET IT
Times cited: 88
A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Academic Article GET IT
Times cited: 25
Discriminatory accuracy and potential clinical utility of genomic profiling for breast cancer risk in BRCA-negative women. Breast cancer research and treatment. 2010 Academic Article GET IT
Times cited: 15
Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers. Journal of medical genetics. 2010 Academic Article GET IT
Times cited: 77
Genome-wide association studies of cancer predisposition. Hematology/oncology clinics of North America. 2010 Review GET IT
Times cited: 35
Inherited predisposition to cancer: introduction and overview. Hematology/oncology clinics of North America. 2010 Review GET IT
Times cited: 9
New pharmacogenomic paradigm in breast cancer treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010 Editorial Article GET IT
Times cited: 11
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (London, England). 2010 Academic Article GET IT
Times cited: 1365
CHEK2, breast cancer, and the understanding of clinical utility. Clinical genetics. 2010 Editorial Article GET IT
Times cited: 12
Genetic analysis of the early natural history of epithelial ovarian carcinoma. PloS one. 2010 Academic Article GET IT
Times cited: 87
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer research. 2010 Academic Article GET IT
Times cited: 65
Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families. Breast cancer research and treatment. 2010 Academic Article GET IT
Times cited: 15
Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 245
Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 79
Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2. Breast cancer research and treatment. 2010 Academic Article GET IT
Times cited: 46
Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer. Oncology (Williston Park, N.Y.). 2010 Information Resource GET IT
Times cited: 31
Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer. Cancer journal (Sudbury, Mass.). 2010 Information Resource GET IT
Times cited: 51
Functional redundancy of exon 12 of BRCA2 revealed by a comprehensive analysis of the c.6853A>G (p.I2285V) variant. Human mutation. 2009 Academic Article GET IT
Times cited: 30
Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 42
Inherited predisposition to gastrointestinal stromal tumor. Hematology/oncology clinics of North America. 2009 Review GET IT
Times cited: 30
Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers. Journal of the National Cancer Institute. 2009 Academic Article GET IT
Times cited: 97
BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 184
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Cancer. 2008 Conference Paper GET IT
Times cited: 72
Prolonged dose-dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible. Clinical breast cancer. 2008 Academic Article GET IT
Times cited: 6
Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update. Breast cancer research and treatment. 2008 Academic Article GET IT
Times cited: 27
The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 48
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 517
Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer. Breast cancer research and treatment. 2007 Academic Article GET IT
Times cited: 24
BRCA mutations in women with ductal carcinoma in situ. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 28
Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. Annals of surgical oncology. 2007 Academic Article GET IT
Times cited: 72
Increased dose density is feasible: a pilot study of adjuvant epirubicin and cyclophosphamide followed by paclitaxel, at 10- or 11-day intervals with filgrastim support in women with breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Academic Article GET IT
Times cited: 9
Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2006 Academic Article GET IT
Times cited: 58
Protecting the privacy of third-party information: recommendations for social and behavioral health researchers. Social science & medicine. 2006 Academic Article GET IT
Times cited: 8
A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy. Journal of the American Geriatrics Society. 2006 Academic Article GET IT
Times cited: 70
Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. Breast cancer research and treatment. 2006 Academic Article GET IT
Times cited: 74
Update on hereditary breast cancer. Current oncology reports. 2006 Review GET IT
Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. Journal of the National Cancer Institute. 2005 Academic Article GET IT
Times cited: 72
Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up. Cancer. 2005 Academic Article GET IT
Times cited: 19
A comparison of bilateral breast cancers in BRCA carriers. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2005 Academic Article GET IT
Times cited: 44
Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. Cancer. 2005 Academic Article GET IT
Times cited: 116
Evaluation of germline PTEN mutations in endometrial cancer patients. Gynecologic oncology. 2005 Academic Article GET IT
Times cited: 39
The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds. Familial cancer. 2005 Academic Article GET IT
Times cited: 23
Breast MRI for women with hereditary cancer risk. JAMA. 2004 Editorial Article GET IT
Times cited: 35
Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 28
Increased progesterone receptor expression in benign epithelium of BRCA1-related breast cancers. Cancer research. 2004 Academic Article GET IT
Times cited: 35
BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 125
Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 100
Ductal lavage in patients undergoing mastectomy for mammary carcinoma: a correlative study. Cancer. 2003 Academic Article GET IT
Times cited: 41
Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Information Resource GET IT
Times cited: 164
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast cancer research : BCR. 2003 Academic Article GET IT
Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. Journal of the National Cancer Institute. 2003 Academic Article GET IT
Times cited: 142
MRI of occult breast carcinoma in a high-risk population. AJR. American journal of roentgenology. 2003 Academic Article GET IT
Times cited: 283
Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Academic Article GET IT
Times cited: 312
The place for politics?. Lancet (London, England). 2003 Letter GET IT
Times cited: 1
Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life. Gynecologic oncology. 2003 Academic Article GET IT
Times cited: 34
Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecologic oncology. 2003 Academic Article GET IT
Times cited: 109
Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer. 2003 Academic Article GET IT
Times cited: 69
Frequency of CHEK2*1100delC in New York breast cancer cases and controls. BMC medical genetics. 2003 Academic Article GET IT
Times cited: 106
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Journal of the National Cancer Institute. 2002 Academic Article GET IT
Times cited: 297
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 136
Rare variants of ATM and risk for Hodgkin's disease and radiation-associated breast cancers. Clinical cancer research : an official journal of the American Association for Cancer Research. 2002 Academic Article GET IT
Times cited: 36
Clinical considerations in the management of individuals at risk for hereditary breast and ovarian cancer. Cancer control : journal of the Moffitt Cancer Center. 2002 Review GET IT
Times cited: 31
Tamoxifen for primary breast cancer prevention in BRCA heterozygotes. European journal of cancer. 2002 Academic Article GET IT
Times cited: 5
Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers. Oncogene. 2002 Academic Article GET IT
Times cited: 30
Considerations in genetic counseling for inherited breast cancer predisposition. Seminars in radiation oncology. 2002 Academic Article GET IT
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. The New England journal of medicine. 2002 Academic Article GET IT
Times cited: 1087
Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002 Academic Article GET IT
Times cited: 385
Unique de novo mutation of BRCA2 in a woman with early onset breast cancer. Journal of medical genetics. 2002 Article GET IT
Times cited: 21
Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations. Genetics in medicine : official journal of the American College of Medical Genetics. 2001 Academic Article GET IT
The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2001 Academic Article GET IT
Times cited: 190
Risk of endometrial carcinoma associated with BRCA mutation. Gynecologic oncology. 2001 Academic Article GET IT
Times cited: 127
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet (London, England). 2000 Academic Article GET IT
Times cited: 480
Are BRCA1- and BRCA2-associated breast cancers different? Prognosis of BRCA1-associated breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Review GET IT
Times cited: 16
Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. Cancer. 2000 Academic Article GET IT
Times cited: 92
Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. Journal of the National Cancer Institute. 1999 Academic Article GET IT
Times cited: 145
Localized male breast carcinoma and family history. An analysis of 142 patients. Cancer. 1999 Academic Article GET IT
Times cited: 59
Molecular genetic characterization of BRCA1- and BRCA2-linked hereditary ovarian cancers. Cancer research. 1998 Academic Article GET IT
Times cited: 90
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
Times cited: 400
BRCA-associated breast cancer in young women. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer. Genetic testing. 1997 Academic Article GET IT
Times cited: 42
Phase II study of fluorouracil, leucovorin, and interferon alfa-2a in metastatic colorectal carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993 Academic Article GET IT
Times cited: 60

more ...

less ...

Background

education and training

M.D., University of Virginia School of Medicine 1986
B.S., Washington and Lee University 1982

Contact

full name

Mark Robson

VIVO Weill Cornell Medical College

Mark Robson Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name